Yun M. Shim, MD
Dr. Yun Shim is a pulmonologist and researcher at Weill Cornell Medicine and New York-Presbyterian/Weill Cornell Medical Center. He is known for pioneering research in advanced lung imaging and for treating interstitial lung disease and obstructive airways disease.
Education and Career
Dr. Shim attended medical school at the Medical College of Virginia/Virginia Commonwealth University. He completed his internship and residency in Internal Medicine at Northwestern University.
He then pursued a post-doctoral fellowship in Pulmonary Disease and Critical Care Medicine at Yale University, where he also completed an additional fellowship in Advanced Asthma and Obstructive Airway Disease. He is board-certified in Internal Medicine, Pulmonary Disease, and Critical Care Medicine.[1]
Dr. Shim is currently the chief of the Division of Pulmonary and Critical Care Medicine at Weill Cornell Medicine and New York-Presbyterian/Weill Cornell Medical Center. He leads a team of physicians treating pulmonary and critical care conditions in intensive care.[1]
Dr. Shim also leads research efforts and education at Weill Cornell. He works to expand access to critical care for pulmonary conditions, including lung transplantation.
Professional Memberships
Dr. Shim is a fellow of the American College of Chest Physicians and a member of the American Thoracic Society, the American College of Physicians, and the Society of Hospital Medicine.
Research
Dr. Shim is active in research. His past laboratory studied therapeutics and drug discovery; in vivo lung imaging using hyperpolarized gas MRI; obstructive lung diseases; the role of obesity and exercise in the pathogenesis of asthma; the role of exercise and COPD outcomes; and lung cancer.[1] He now leads research efforts at Weill Cornell.
Funded projects include:
- NIH/ULTR003015 (Health Effects of JUUL in Healthy Young Electronic Cigarette Users)
- NIH/NHLBI 1R01HL (Hyperpolarized Xenon-129 MRI: a new multi-dimensional biomarker to determine pulmonary physiologic responses to COPD therapeutics)
- DOD W0259_18_WR (A dual approach to combating infection by targeting the host’s inflammatory response and bacterial pathogens)
- NIH/NHLBI 1R43HL147667 (Respiratory Oxygen Adherence Monitor for COPD patient)
- Genentech (129Xe MRI assessment of disease progression in patients with COPD treated with standard-of-care medications with or without daily open-label azithromycin treatment to prevent acute exacerbation)
